date" for cases and their matched controls. The pre-analysis lead-in period was defined as the 12 month period from 01/Jan/2008 to 31/Dec/2008, inclusive. Thus, the study inclusion period contains all time from 01/Jan/2008 to 31/Dec/2009, inclusive. A base population was defined containing all patients eligible for this study. This was the denominator for calculations of the population prevalence of epilepsy. All cases and controls were selected from this population. For inclusion in the base population, a patient must have been:
• registered on the database for the full lead-in period to allow the identification of existing epilepsy patients.
• registered on the database for the full analysis period to allow the characterisation of patients' current medication and comorbidities.
• aged between 0 and 120 years inclusive, on the index date For the IHCIS, the analyses of medication use were restricted to those cases with full pharmacy benefits throughout the analysis period and no gaps in pharmacy benefit greater than one day during the analysis period.
Analysis 1: prevalence of epilepsy
The prevalence of epilepsy on the index date was determined, by gender and age category, as appropriate. The denominator was taken as all patients within the base population. In IHCIS, the numerator was calculated as all patients (within the denominator population) with two or more records of epilepsy, and 30 days or more between the first and last record of epilepsy. In GPRD, the numerator was calculated as all patients (within the denominator population) with an epilepsy diagnosis prior to the index date, and at least 2 anti-epileptic drug (AED) prescriptions within -3 and +6 months of any epilepsy diagnosis code AND at least 1 AED prescription within the lead-in or analysis period. For both databases, at least one of the diagnoses must be on, or before, the index date.
Analysis 2: listing of comorbidities in epilepsy patients
The prevalence of comorbidities within the epilepsy and control populations was determined. A patient was considered to have a comorbidity if they had one or more records of this condition within the time period being considered. Prevalence of comorbid disease in the epilepsy population was calculated as the number of epilepsy cases with a record of the disease (within the time periods defined below) divided by the total number of epilepsy cases. Prevalence of comorbid diseases in the controls were similarly calculated. Analyses were repeated for two time periods, (1) the analysis period and (2) the analysis period, and any time before, within the period of continuous enrollment. In GPRD, the comorbidities are listed as defined by disease headings which were based on the Meddra Dictionary and were reviewed by clinicians. A Read/MedDRA (version 13.0) mapping was created using the available Read/MedDRA (version 6) dictionary and the 2010-AB release of the Unified Medical Language System (UMLS). Approximately 41% of events were not mapped, but many of the events remaining unmapped were not of clinical significance. Some of these were mapped by further review of terms. In IHCIS, comorbidities are reported by Clinical Classifications Software (CCS) level 4 (HCUP, 2011).
In addition, there were a number of conditions previously associated with epilepsy that were specifically explored including: depression, anxiety, bipolar disorder, suicidality, and migraine. These conditions were defined by clinician-reviewed coding lists using GPRD GOLD READ medical codes or ICD-9 codes for IHCIS. In GPRD, medications are listed as defined by British National formulary (BNF) class, and in IHCIS by Universal System Classification (USC) Fourth Level. The USC is a categorization system, developed by IMS, to resolve a need for therapeutic classification of pharmaceutical products; the USC is widely accepted in North America as the standard for pharmaceutical product classification.
Analysis 3: comparative analyses of the occurrence co-morbidities
The relative prevalence of co-morbidities in epilepsy cases and matched controls was assessed. Unstratified matched analyses were conducted via conditional logistic regression using the SAS Proc PHREG procedure. Stratified analyses were conducted via the Fisher Exact tests using the SAS Proc FREQ procedure. Odds ratios (ORs) and 95% confidence intervals are presented (Note: p-values are not presented). Since these were exploratory (rather than hypothesis testing) analyses, and sample sizes are not based on statistical considerations, there was no adjustment for multiple testing. ORs are only presented where there were at least five patients in both the case and control populations with a record of the comorbidity within the time period being considered. Results are presented for the 25 most frequent comorbidities amongst cases, and for the 25 highest ORs comparing cases and controls.
Analysis 4: listing of prescribed medications used by epilepsy cases during a one-year period of observation
The prevalence of drug use within the analysis period is presented for the epilepsy population. A patient was considered to be using the drug of interest if they were issued a prescription during the analysis period. The prevalence of drug use was calculated as the number of eligible cases with a record of use within the analysis period divided by the total number of eligible cases. Results are presented for cases only, and reported at Universal System Classification Fourth Level.
Results
There were 27,328 active epilepsy cases and 27,328 matched controls identified in the UK GPRD, and 83,045 active epilepsy cases and 83,045 controls identified from the IHCIS. Active epilepsy in GPRD was defined if a patient diagnosed with epilepsy had at least one AED prescription within the one-year lead-in or one-year analysis period. Active epilepsy in the IHCIS was defined if the patient had at least one diagnosis code within the lead-in or analysis period. The overall prevalence of active epilepsy was 0.8% in GPRD and 0.5% in IHCIS. The prevalence in GPRD increased with age and was highest in the age group 65 years and older. The prevalence was similar across the age groups in IHCIS with a peak of 0.5% in the age group 45 to 64 years. The studies within the US claims database (IHCIS) and UK general practice database (GPRD) compared the prevalence of a range of psychiatric conditions including anxiety, (Table 1&Table 2). These psychiatric conditions were significantly more common in epilepsy cases than in controls (OR > 1.0, and lower bound of 95% CI excluding 1.0). The highest ORs were for suicidality, bipolar disorder and schizophrenia. Migraine was also included in the analyses, and it was significantly more common among cases than controls for the time period during or before analysis period. However, the association was not significant for the analysis period only in GPRD, and the associations were stronger in IHCIS than GPRD. Given the chronic nature of these conditions the prevalence was considered both during and prior to the analysis period (i.e. the latter period represented the patients' medical histories). The top 25 most common diagnosed comorbidities among cases are reported for within the analysis period (Table 3 & Table 7 ) and within the analysis period or before (Table 4 & Table  8 ), for GPRD and IHCIS respectively. As expected, the medical condition headings related to epilepsy, seizures and convulsions were at the top of the lists. Other conditions included respiratory infections, skin conditions, and hypertension. The latter conditions were also common in controls.
The top 25 diagnosed comorbidities with the highest ORs comparing cases to controls were reported for the analysis period (Table 5 & Table 9 ) and within the analysis period or before (Table 6 & Table 10 ), for GPRD and IHCIS respectively. These listings can be considered for generating hypotheses about the associations between epilepsy and other conditions, though temporality cannot be established. In the GPRD, mental retardation had a high OR of 24.9 (95%CI: 12.3-50.4) during the analysis period. During the GPRD analysis period, the conditions with the highest ORs included many neurological conditions and behaviour and socialisation disturbances (Table  5 ). In the GPRD analysis period or ever before, the conditions with the highest ORs also included neurological and developmental conditions, and the highest ORs were 50.7 (95%CI: 28.0-92.1) for "Cerebral disorders congenital", 38.1 (95%CI: 20.9-69.3) for "Congenital and peripartum cerebral disorders", and 33.9 (95%CI: 16.8-68.4) for "Neonatal neurological system disorders NEC" ( Table 6 ). The highest OR in the IHCIS was for intellectual disabilities, 143.1 (95%CI: 84.6-241.9) during the analysis period, and 79.8 (95%CI: 60.1-106.1) during the analysis period or ever before. The other conditions with high ORs included neurological disorders, cerebrovascular disease, developmental and learning disorders, and mental disorders ( Table  9 & Table 10 ). Medication use was reported for the analysis year, 2009, for epilepsy cases only (N=27,328 GPRD; N= 46,912 IHCIS). For IHCIS, only individuals with full pharmacy benefits throughout the year 2009 were included in medication analyses. The proportion of patients using anti-depressants and anti-epileptic drugs were reported using clinician-reviewed drug coding lists (Table 11 & Table 13 ). In the GPRD, 97% of the epilepsy cases had a prescription for an anti-epileptic drug in the analysis period, as expected since AED use either in the lead-in or analysis period was a requirement of the case definition (3% of cases only had AED use in the lead-in period). Eighteen percent of cases had a prescription for antidepressants in the one-year analysis period. In the IHCIS, 76% of epilepsy patients had a prescription for an AED, and 22% for anti-depressants in 2009. The 24% of epilepsy cases who did not have an AED in the analysis period may either not have had pharmacy benefit, or they were not prescribed an AED in that time period. However, the relative proportions of patients using each type of AED are of interest, and there are differences in the AED use between the UK GPRD and US IHCIS. Two of the older AEDs, valproate (34%) and carbamazepine (32%) were the most frequently used AEDs among epilepsy patients in the GPRD, followed by lamotrigine (18%) and phenytoin (17%). Lamotrigine (15%) and phenytoin (15%) were the most commonly used AEDs in the IHCIS in 2009, followed by carbamazepine (12%) and topiramate (9%). The top 25 most commonly prescribed medication categories in a one year time period, 2009, are reported for GPRD (Table 12 ) and IHCIS (Table 14) . As in (Table 11) , drugs classified as "Control of Epilepsy" were the most commonly prescribed in GPRD (97.3%). Other common medications were neuropathic pain (52.3%), non-opioid analgesics (39.7%), anti-manic drugs (32.4%), non-steroidal anti-inflammatory drugs (30.2%), opioid analgesics (23.8%), broad spectrum penicillins (21.1%), and statins (20.2%). In the IHCIS, 74% of epilepsy patients had a prescription in the "Seizure disorders" drug category during 2009. The other frequently prescribed medications were codeine (23%), extended spectrum macroli (19%), benzodiazepines (17%), and selective serotonin reuptake inhibitors (SSRI, 15%). 
Discussion
Electronic medical record systems provide an opportunity to identify treatment patterns and comorbidities in a large diagnosed disease population. They also allow for comparisons between the relative prevalence estimates of various comorbidities within the same data source. The comorbidities were ranked by how prevalent they were in epilepsy cases, and then by the ORs comparing cases to controls. The conditions with the highest ORs have the strongest associations with epilepsy compared to matched controls, therefore these findings may be hypothesis-generating for conditions related to epilepsy, though temporality cannot be established in this cross-sectional study. For instance, these can be tested as risk factors for epilepsy; conversely, epilepsy can be examined as a risk factor for these associated conditions. The definition of both cases and controls requires that patients are registered throughout the full lead-in and analysis periods. The lead-in period is used to identify existing epilepsy patients to ensure that all cases have epilepsy prior to the start of the observation period. This ensures that patients are "at risk" of receiving management for epilepsy throughout the observation period when the patient's status is being assessed. This cross sectional approach, based on a set calendar index date, means there is no restriction of the duration of epilepsy prior to the start of observation, and the population is likely to contain both prevalent and newly-diagnosed epilepsy cases. The use of an index date tied to an individual patient (such as their first diagnosis on a database) is another possible approach, which is more tailored incident cases (or patients at an earlier stage of the disease) and historical rather than recent management patterns. Diagnosed prevalence rates were similar in a US insurance claims database (0.5%) and a UK general practice-based electronic medical record system (0.8%), although peak age prevalence differed, likely based on the patient populations covered by these systems. The IHCIS system under-represents the elderly population, because it mainly consists of the employed, insured population. These prevalence estimates are similar to those reported in the literature for studies with records-based methodology, ranging from 3 to 8 per 1000 persons (Banerjee et al., 2009 ). Many diagnosed comorbidities, including psychiatric and neurological comorbidities, were more prevalent in the patients with epilepsy compared to matched controls. A previous study in the GPRD also reported that many conditions were associated with epilepsy . The current study supports the evidence that the burden of epilepsy along with its comorbidities is high compared to the general population. Major depression is a common co-morbidity of epilepsy with at least 20% of epilepsy patients experiencing mild to severe depressive symptoms (O'Donoghue et al., 1999; Mendez et al., 1986; Hermann et al., 1986; Baker et al., 1996; Cramer et al., 2004; Boylan et al., 2004; Beghi et al., 2002 ). In the current study, 29% of patients with epilepsy in the GPRD (OR= 1.5, 95%CI: 1.4-1.5), and 24% of patients with epilepsy in the IHCIS (OR=2.6, 95%CI: 2.5-2.7) had a diagnosis of depression in the analysis period or before. Studies using structured psychiatric interviews in epilepsy clinics, likely to represent more severe epilepsy patients, have reported a prevalence of major depression of up to 55% (Mendez et al., 1996) . However, the cross-sectional nature of most studies prevents inferences concerning the temporal order of disease development. When longitudinal analyses have been completed a history of major depression has been associated with an increased risk for incident epilepsy and first unprovoked seizure (Nilsson et al., 2003; Forsgren & Nystrom 1990; Hesdorffer et al., 2006; Hesdorffer et al., 2000) . Certain epilepsy types may be at increased risk of depression: the mean estimated lifetime prevalence of depression is 30% for patients with temporal lobe epilepsy and refractory epilepsy with corresponding risks in the general population of between 6% and 17% (Glosser et al., 2000) . Studies have consistently identified co-morbid depression as a powerful predictor of poor health related quality of life in epilepsy patients even after adjustment for seizure frequency and severity (Kanner, 2009) . Depression is also a strong predictor for increased suicidality among epilepsy patients (Kanner, 2009) . The prevalence of anxiety disorders is consistently higher (approximately twofold increased risk) among epilepsy patients than the general population. In the current study, 21% of patients with epilepsy in the GPRD (OR= 1.4, 95%CI: 1.3-1.5), and 26% of patients with epilepsy in the IHCIS (OR=2.1, 95%CI: 2.1-2.2) had a diagnosis of anxiety in the analysis period or before. Studies using a range of disease measurement scales, and capturing patients mainly through cross sectional health surveys, have reported point prevalence estimates in epilepsy patients of 11% to 39% Tellez-Zenteno et al., 2007; Edeh & Toone, 1987; Stirne et al., 2005; Kobau et al., 2006) . The variation is likely to reflect the selection of different subsets of the epilepsy population with higher prevalence estimates observed among patients with temporal lobe epilepsy. The prevalence of psychoses in epilepsy, as reported from population-based studies, ranges from 2% to 7% . The prevalence varies by epilepsy type with estimates of 10% to 19% reported among individuals with temporal lobe epilepsy, nearly double the risk associated with generalised epilepsy, though larger differences have been reported in older studies Shukla et al., 1979) . Gender differences have also been reported with females at an increased risk of psychoses. An Icelandic study reported 6% prevalence in males with epilepsy versus 9% in females (Gudmundsson, 1966 ). In the current study, 9% of patients with epilepsy in the IHCIS (OR=9.7, 95%CI: 9.0-10.4) had a diagnosis of psychosis in the analysis period or before. The incidence of psychoses is reported to be 3 to 12 times higher in epilepsy patients than the general population. The range again depends on the epilepsy population sampled (seizure type and severity) as well as the instrument used to diagnose psychosis (Bredkjaer et al., 1998; Torta & Keller, 1999) . Patients undergoing epilepsy surgery are at particular risk of developing psychoses for the first time. Interictal psychoses can develop in 3% to 12% of patients following anterior temporal lobectomy and seizure-related psychoses can affect 1% to 13% of patients Gaitatzis et al., 2004 (2) ). Studies concentrating solely on schizophrenia have reported prevalence estimates of 4% to 18% among patients with epilepsy (the majority suffering from temporal lobe epilepsy) Gaitatzis et al., 2004 (2) ). The expected prevalence of schizophrenia in the general population is 1% (Toone, 2000) . Patients with schizophrenia are also at an increased risk of seizures related to the condition itself and to exposure to psychotropic medications that lower seizure threshold (e.g. clozapine) (Torta & Keller, 1999 ). In the current study, 1% of patients with epilepsy in the GPRD (OR=2.8, 95%CI: 2.5-3.1) had a diagnosis of schizophrenia in the analysis period or before.
Suicide is a much discussed cause of death in epilepsy patients, especially with the recent analysis by the US Food and Drug Administration in 2008 that showed an association between AEDs and suicidality in pooled clinical trials. Population-based studies report that between 0% and 9% (Sweden and Iceland, respectively) of deaths among patients with epilepsy result from suicide (Tomson et al., 2004) . However it is not clear whether epilepsy or its treatment increases the risk of suicide: suicide attempt has been associated with an increased risk for developing epilepsy indicating the association could represent the recurrence, post epilepsy diagnosis, of an underlying suicidality risk 74. The GPRD and IHCIS results indicate an association between epilepsy diagnosis and suicidality, with an OR of 2.8 (95% CI: 2.5-3.1) in GPRD and 5.5 (95% CI: 5.2-6.0) in IHCIS for during or ever before the analysis period. The reported prevalence of migraine among epilepsy patients ranges from 8% to 23% (Marks & Ehrenberg, 1993) compared with 12% in the general population (Lipton et al., 2007) . While the majority of studies report the risk of migraine to be two-fold greater among epilepsy patients , two studies failed to confirm this association (KaraaliSavrun et al., 2002; Nuyen et al., 2006) . This discordance is most likely due to differences in migraine definition and the absence of well defined control groups in some studies. Recent studies indicate that the association is primarily with migraine with aura, though the absolute prevalence of migraine with aura among epilepsy patients has yet to be reported (Piccinelli et al., 2006) . The IHCIS and GPRD database studies supported a positive association between epilepsy and migraine. A history of diagnosed migraine was present in 16% of epilepsy cases and 5% of controls in the IHCIS database study (OR = 3.7, 95% CI: 3.6-3.8). In the GPRD database, 9% of cases and 7% of controls had a history of diagnosed migraine (OR= 1.3, 95% CI: 1.3-1.4). The differential prevalences between the databases likely reflect between-country differences in diagnostics, awareness and treatment of migraine. The current medication data was only reported for the patients with epilepsy to determine the most commonly used medications among patients with epilepsy. The most common AEDs varied between the US and UK databases. This is likely due to different treatment patterns and guidelines in the two countries. It has previously been shown that there is an association between the first AED prescribed after diagnosis of and history of psychiatric disorders, including depression and bipolar disorder, and the differential prescribing varied between the US and UK (Ishihara et al., 2010) . One potential use of these data is to characterise polypharmacy patterns to inform potential drug interaction studies. Since the majority of patients are prescribed AEDs, the list identifies other medication types that are commonly used among the epilepsy patients. The study should be interpreted in the context of its strengths and potential limitations. The strengths of the study include the large sizes of the databases, and the availability of detailed diagnosis and medication records. The GPRD is representative of the general population of the UK, and the IHCIS is representative of the US insured population. The IHCIS database is a large sample of people in the US covered by private insurance plans. Therefore results of this study may not be representative of US patients who receive healthcare through government organizations (e.g., Medicare, Medicaid) or who lack health insurance; for instance, these patients may be more likely to receive generic or older AEDs. In both databases, only diagnosed diseases are recorded, and therefore patients had to present to healthcare to be diagnosed with conditions or prescribed medications. There is a possibility of confounding by consultation frequency because patients with epilepsy or other chronic medical conditions will be more likely to be seen by healthcare providers compared to the general population. The results of this study can be used to generate hypotheses about which medical conditions may be associated with epilepsy (either as risk factors for epilepsy, or resulting from epilepsy). Understanding the comorbidities and medication patterns in epilepsy also informs the effects of eligibility criteria on clinical trial recruitment, and facilitates assessments of potential safety signals that may arise in clinical trials (e.g. if a conditions is more common within the disease population at baseline, then this should be taken into account in evaluating whether exposure to a medication is associated with that condition).
Conclusion
In conclusion, psychiatric, neurological and other comorbidities are more common in patients with epilepsy, compared to age-, sex-matched controls. The results of this study provide hypotheses about conditions which may be associated with epilepsy, and these may be the subject for further investigation. Among patients with epilepsy, the most commonly prescribed medications varied between the UK and US. Two of the older AEDs, valproate and carbamazepine, were the most commonly prescribed AEDs in 2009 amongst epilepsy patients in GPRD. Lamotrigine and phenytoin were the most commonly prescribed AEDs to patients with epilepsy in 2009 within IHCIS. The most commonly prescribed medications among the epilepsy patient population, aside from AEDs, included analgesics, non-steroidal anti-inflammatory drugs, extended spectrum macroli (anti-biotics), selective serotonin reuptake inhibitors, and statins. The list of commonly prescribed medications in the epilepsy patient population can give an indication as to which drugs to consider for possible drug-drug interactions.
